Clinical trial
Fenretinide in Treating Patients With Cervical Neoplasia
NCT00003075 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003075 |
|---|---|
| Title | Fenretinide in Treating Patients With Cervical Neoplasia |
| Official title | A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cervical Cancer, Precancerous Condition |
| Intervention type | Drug, Other |
| Interventions | Fenretinide, Placebo |
| Enrollment | 39 |
| Start date | Mar 5, 1993 |
| Primary completion | May 1, 2001 |
| Completion | May 1, 2001 |
| First posted | May 27, 2004 |
| Last update posted | Oct 24, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: